EcoDrugPlus

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSBSLG00000014433
Gene Symbol: PSENEN
3 Cross references
185 Possible Orthologues:

Presenilin-1-Like

Ensembl ID : ENSBSLG00000025994
Gene Symbol: LOC114848802
3 Cross references
202 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme-Like

Ensembl ID : ENSBSLG00000012746
Gene Symbol: LOC114860924
3 Cross references
403 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSBSLG00000006178
Gene Symbol: LOC114865711
3 Cross references
250 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSBSLG00000016101
Gene Symbol: LOC114848179
3 Cross references
257 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSBSLG00000026633
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSBSLG00000000324
Gene Symbol: PTGDR2
3 Cross references
134 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSBSLG00000018980
Gene Symbol: PTGDR2
1 Cross references
145 Possible Orthologues:

Prostaglandin E Receptor 1b (Subtype Ep1)

Ensembl ID : ENSBSLG00000004461
Gene Symbol: PTGER1B
1 Cross references
163 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSBSLG00000001303
Gene Symbol: PTGER3
3 Cross references
196 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSBSLG00000003302
Gene Symbol: LOC114860710
3 Cross references
171 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype-Like

Ensembl ID : ENSBSLG00000013654
Gene Symbol: LOC114850065
3 Cross references
172 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).